サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1761523

動物用狂犬病ワクチンの世界市場の評価：用途別、流通チャネル別、地域別、機会、予測（2018年～2032年）

Global Rabies Veterinary Vaccines Market Assessment, By Application [Companion Animals, Livestock Animals, Others], By Distribution Channel [Retail, E-Commerce, Hospital/Clinic Pharmacies], By Region, Opportunities and Forecast, 2018-2032F

出版日
ページ情報
英文 232 Pages
納期
3～5営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=147.66円
動物用狂犬病ワクチンの世界市場の評価：用途別、流通チャネル別、地域別、機会、予測（2018年～2032年）
出版日: 2025年07月03日
発行: Markets & Data
ページ情報: 英文 232 Pages
納期: 3～5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の動物用狂犬病ワクチンの市場規模は、2024年の6億1,254万米ドルから2032年に8億3,959万米ドルに達すると予測され、2025年～2032年の予測期間にCAGRで4.02%の成長が見込まれます。世界市場の成長の主因は社会的理解の拡大であり、急速に進む世界中での都市の統合、政府の規則、狂犬病ウイルスの変化、世界の旅行活動の活発化、消費者の消費力の増加もその要因となっています。

複数の国が、疾患の発生を食い止めるための予防措置としてペットの狂犬病予防接種を義務付けており、同時に人への感染リスクを最小化しています。さまざまな地域での狂犬病対策は動物用ワクチンに大きく依存しており、犬が媒介する人間の狂犬病を阻止するための世界的な取り組みも支援しています。医療当局は、特にリスクの高い地域において、予防レベルを維持するために定期的な間隔でブースターワクチン接種を受けることを推奨しており、世界の動物用狂犬病ワクチン市場の成長が促進されています。ワクチン接種の取り組みと、公共啓蒙活動や野良動物防除プログラムを組み合わせることは狂犬病予防の主な方法であり、これは人と動物の両方を守ります。

例えば2024年3月、Spanish National Research Council（Consejo Superior de Investigaciones Cientificas）とZendalグループの共同研究により、動物から人にも感染する可能性のある深刻な人獣共通感染症である犬リーシュマニア症に対する世界初のDNAワクチン、Neoleishが上市されました。

当レポートでは、世界の動物用狂犬病ワクチン市場について調査分析し、市場規模と予測、市場力学、主要企業の情勢などを提供しています。

目次

第1章 プロジェクトの範囲と定義

第2章 調査手法

第3章 米国関税の影響

第4章 エグゼクティブサマリー

第5章 世界の動物用狂犬病ワクチン市場の見通し（2018年～2032年）

  • 市場規模の分析と予測
    • 金額
  • 市場シェアの分析と予測
    • 用途別
      • コンパニオンアニマル
      • 家畜
      • その他
    • 流通チャネル別
      • 小売
      • eコマース
      • 病院/診療所薬局
    • 地域別
      • 北米
      • 欧州
      • アジア太平洋
      • 南米
      • 中東・アフリカ
    • 市場シェア分析：企業別（上位5社とその他）（金額）（2024年）
  • 市場マップ分析（2024年）
    • 用途別
    • 流通チャネル別
    • 地域別

第6章 北米の動物用狂犬病ワクチン市場の見通し（2018年～2032年）

  • 市場規模の分析と予測
    • 金額
  • 市場シェアの分析と予測
    • 用途別
      • コンパニオンアニマル
      • 家畜
      • その他
    • 流通チャネル別
      • 小売
      • eコマース
      • 病院/診療所薬局
    • シェア：国別
      • 米国
      • カナダ
      • メキシコ
  • 各国の市場の評価
    • 米国の動物用狂犬病ワクチン市場の見通し（2018年～2032年）
      • 市場規模の分析と予測
      • 市場シェアの分析と予測
    • カナダ
    • メキシコ

第7章 欧州の動物用狂犬病ワクチン市場の見通し（2018年～2032年）

  • ドイツ
  • フランス
  • イタリア
  • 英国
  • ロシア
  • オランダ
  • スペイン
  • トルコ
  • ポーランド

第8章 アジア太平洋の動物用狂犬病ワクチン市場の見通し（2018年～2032年）

  • インド
  • 中国
  • 日本
  • オーストラリア
  • ベトナム
  • 韓国
  • インドネシア
  • フィリピン

第9章 南米の動物用狂犬病ワクチン市場の見通し（2018年～2032年）

  • ブラジル
  • アルゼンチン

第10章 中東・アフリカの動物用狂犬病ワクチン市場の見通し（2018年～2032年）

  • サウジアラビア
  • アラブ首長国連邦
  • 南アフリカ

第11章 需給の分析

第12章 バリューチェーン分析

第13章 ポーターのファイブフォース分析

第14章 PESTLE分析

第15章 価格分析

第16章 市場力学

  • 市場促進要因
  • 市場の課題

第17章 市場動向と発展

  • 技術分析

第18章 規制枠組みとイノベーション

第19章 ケーススタディ

第20章 競合情勢

  • マーケットリーダー上位5社の競合マトリクス
  • 上位5社のSWOT分析
  • 主要企業上位10社の情勢
    • Zoetis Inc.
    • Merck & Co., Inc
    • C.H. Boehringer Sohn AG & Co. KG. (Parent Company)
    • ELANCO ANIMAL HEALTH INCORPORATED
    • Virbac SA
    • Laboratorios HIPRA, S.A.
    • Neogen Corporation
    • HESTER BIOSCIENCES LIMITED
    • Phibro Animal Health Corporation
    • Ceva Sante Animale SA

第21章 戦略的提言

第22章 調査会社について・免責事項

図表

List of Tables

  • Table 1. Competition Matrix of Top 5 Market Leaders
  • Table 2. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 3. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Rabies Veterinary Vaccines Market, By Value, In USD Million, 2018-2032F
  • Figure 2. Global Rabies Veterinary Vaccines Market Share (%), By Application, 2018-2032F
  • Figure 3. Global Rabies Veterinary Vaccines Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 4. Global Rabies Veterinary Vaccines Market Share (%), By Region, 2018-2032F
  • Figure 5. North America Rabies Veterinary Vaccines Market, By Value, In USD Million, 2018-2032F
  • Figure 6. North America Rabies Veterinary Vaccines Market Share (%), By Application, 2018-2032F
  • Figure 7. North America Rabies Veterinary Vaccines Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 8. North America Rabies Veterinary Vaccines Market Share (%), By Country, 2018-2032F
  • Figure 9. United States Rabies Veterinary Vaccines Market, By Value, In USD Million, 2018-2032F
  • Figure 10. United States Rabies Veterinary Vaccines Market Share (%), By Application, 2018-2032F
  • Figure 11. United States Rabies Veterinary Vaccines Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 12. Canada Rabies Veterinary Vaccines Market, By Value, In USD Million, 2018-2032F
  • Figure 13. Canada Rabies Veterinary Vaccines Market Share (%), By Application, 2018-2032F
  • Figure 14. Canada Rabies Veterinary Vaccines Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 15. Mexico Rabies Veterinary Vaccines Market, By Value, In USD Million, 2018-2032F
  • Figure 16. Mexico Rabies Veterinary Vaccines Market Share (%), By Application, 2018-2032F
  • Figure 17. Mexico Rabies Veterinary Vaccines Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 18. Europe Rabies Veterinary Vaccines Market, By Value, In USD Million, 2018-2032F
  • Figure 19. Europe Rabies Veterinary Vaccines Market Share (%), By Application, 2018-2032F
  • Figure 20. Europe Rabies Veterinary Vaccines Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 21. Europe Rabies Veterinary Vaccines Market Share (%), By Country, 2018-2032F
  • Figure 22. Germany Rabies Veterinary Vaccines Market, By Value, In USD Million, 2018-2032F
  • Figure 23. Germany Rabies Veterinary Vaccines Market Share (%), By Application, 2018-2032F
  • Figure 24. Germany Rabies Veterinary Vaccines Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 25. France Rabies Veterinary Vaccines Market, By Value, In USD Million, 2018-2032F
  • Figure 26. France Rabies Veterinary Vaccines Market Share (%), By Application, 2018-2032F
  • Figure 27. France Rabies Veterinary Vaccines Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 28. Italy Rabies Veterinary Vaccines Market, By Value, In USD Million, 2018-2032F
  • Figure 29. Italy Rabies Veterinary Vaccines Market Share (%), By Application, 2018-2032F
  • Figure 30. Italy Rabies Veterinary Vaccines Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 31. United Kingdom Rabies Veterinary Vaccines Market, By Value, In USD Million, 2018-2032F
  • Figure 32. United Kingdom Rabies Veterinary Vaccines Market Share (%), By Application, 2018-2032F
  • Figure 33. United Kingdom Rabies Veterinary Vaccines Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 34. Russia Rabies Veterinary Vaccines Market, By Value, In USD Million, 2018-2032F
  • Figure 35. Russia Rabies Veterinary Vaccines Market Share (%), By Application, 2018-2032F
  • Figure 36. Russia Rabies Veterinary Vaccines Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 37. Netherlands Rabies Veterinary Vaccines Market, By Value, In USD Million, 2018-2032F
  • Figure 38. Netherlands Rabies Veterinary Vaccines Market Share (%), By Application, 2018-2032F
  • Figure 39. Netherlands Rabies Veterinary Vaccines Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 40. Spain Rabies Veterinary Vaccines Market, By Value, In USD Million, 2018-2032F
  • Figure 41. Spain Rabies Veterinary Vaccines Market Share (%), By Application, 2018-2032F
  • Figure 42. Spain Rabies Veterinary Vaccines Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 43. Turkey Rabies Veterinary Vaccines Market, By Value, In USD Million, 2018-2032F
  • Figure 44. Turkey Rabies Veterinary Vaccines Market Share (%), By Application, 2018-2032F
  • Figure 45. Turkey Rabies Veterinary Vaccines Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 46. Poland Rabies Veterinary Vaccines Market, By Value, In USD Million, 2018-2032F
  • Figure 47. Poland Rabies Veterinary Vaccines Market Share (%), By Application, 2018-2032F
  • Figure 48. Poland Rabies Veterinary Vaccines Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 49. South America Rabies Veterinary Vaccines Market, By Value, In USD Million, 2018-2032F
  • Figure 50. South America Rabies Veterinary Vaccines Market Share (%), By Application, 2018-2032F
  • Figure 51. South America Rabies Veterinary Vaccines Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 52. South America Rabies Veterinary Vaccines Market Share (%), By Country, 2018-2032F
  • Figure 53. Brazil Rabies Veterinary Vaccines Market, By Value, In USD Million, 2018-2032F
  • Figure 54. Brazil Rabies Veterinary Vaccines Market Share (%), By Application, 2018-2032F
  • Figure 55. Brazil Rabies Veterinary Vaccines Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 56. Argentina Rabies Veterinary Vaccines Market, By Value, In USD Million, 2018-2032F
  • Figure 57. Argentina Rabies Veterinary Vaccines Market Share (%), By Application, 2018-2032F
  • Figure 58. Argentina Rabies Veterinary Vaccines Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 59. Asia-Pacific Rabies Veterinary Vaccines Market, By Value, In USD Million, 2018-2032F
  • Figure 60. Asia-Pacific Rabies Veterinary Vaccines Market Share (%), By Application, 2018-2032F
  • Figure 61. Asia-Pacific Rabies Veterinary Vaccines Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 62. Asia-Pacific Rabies Veterinary Vaccines Market Share (%), By Country, 2018-2032F
  • Figure 63. India Rabies Veterinary Vaccines Market, By Value, In USD Million, 2018-2032F
  • Figure 64. India Rabies Veterinary Vaccines Market Share (%), By Application, 2018-2032F
  • Figure 65. India Rabies Veterinary Vaccines Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 66. China Rabies Veterinary Vaccines Market, By Value, In USD Million, 2018-2032F
  • Figure 67. China Rabies Veterinary Vaccines Market Share (%), By Application, 2018-2032F
  • Figure 68. China Rabies Veterinary Vaccines Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 69. Japan Rabies Veterinary Vaccines Market, By Value, In USD Million, 2018-2032F
  • Figure 70. Japan Rabies Veterinary Vaccines Market Share (%), By Application, 2018-2032F
  • Figure 71. Japan Rabies Veterinary Vaccines Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 72. Australia Rabies Veterinary Vaccines Market, By Value, In USD Million, 2018-2032F
  • Figure 73. Australia Rabies Veterinary Vaccines Market Share (%), By Application, 2018-2032F
  • Figure 74. Australia Rabies Veterinary Vaccines Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 75. Vietnam Rabies Veterinary Vaccines Market, By Value, In USD Million, 2018-2032F
  • Figure 76. Vietnam Rabies Veterinary Vaccines Market Share (%), By Application, 2018-2032F
  • Figure 77. Vietnam Rabies Veterinary Vaccines Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 78. South Korea Rabies Veterinary Vaccines Market, By Value, In USD Million, 2018-2032F
  • Figure 79. South Korea Rabies Veterinary Vaccines Market Share (%), By Application, 2018-2032F
  • Figure 80. South Korea Rabies Veterinary Vaccines Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 81. Indonesia Rabies Veterinary Vaccines Market, By Value, In USD Million, 2018-2032F
  • Figure 82. Indonesia Rabies Veterinary Vaccines Market Share (%), By Application, 2018-2032F
  • Figure 83. Indonesia Rabies Veterinary Vaccines Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 84. Philippines Rabies Veterinary Vaccines Market, By Value, In USD Million, 2018-2032F
  • Figure 85. Philippines Rabies Veterinary Vaccines Market Share (%), By Application, 2018-2032F
  • Figure 86. Philippines Rabies Veterinary Vaccines Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 87. Middle East & Africa Rabies Veterinary Vaccines Market, By Value, In USD Million, 2018-2032F
  • Figure 88. Middle East & Africa Rabies Veterinary Vaccines Market Share (%), By Application, 2018-2032F
  • Figure 89. Middle East & Africa Rabies Veterinary Vaccines Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 90. Middle East & Africa Rabies Veterinary Vaccines Market Share (%), By Country, 2018-2032F
  • Figure 91. Saudi Arabia Rabies Veterinary Vaccines Market, By Value, In USD Million, 2018-2032F
  • Figure 92. Saudi Arabia Rabies Veterinary Vaccines Market Share (%), By Application, 2018-2032F
  • Figure 93. Saudi Arabia Rabies Veterinary Vaccines Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 94. UAE Rabies Veterinary Vaccines Market, By Value, In USD Million, 2018-2032F
  • Figure 95. UAE Rabies Veterinary Vaccines Market Share (%), By Application, 2018-2032F
  • Figure 96. UAE Rabies Veterinary Vaccines Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 97. South Africa Rabies Veterinary Vaccines Market, By Value, In USD Million, 2018-2032F
  • Figure 98. South Africa Rabies Veterinary Vaccines Market Share (%), By Application, 2018-2032F
  • Figure 99. South Africa Rabies Veterinary Vaccines Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 100. By Application Map-Market Size (USD Million) & Growth Rate (%), 2024
  • Figure 101. By Distribution Channel Map-Market Size (USD Million) & Growth Rate (%), 2024
  • Figure 102. By Region Map-Market Size (USD Million) & Growth Rate (%), 2024
目次
Product Code: MX13545

Global rabies veterinary vaccines market is projected to witness a CAGR of 4.02% during the forecast period 2025-2032, growing from USD 612.54 million in 2024 to USD 839.59 million in 2032. Global market growth receives its main boost from public understanding expansion, along with fast-paced worldwide integration of cities, government rules, virus rabies change, rising worldwide travel activity, and increasing consumer spending power.

Multiple nations require pet rabies vaccinations as a preventive measure to stop disease outbreaks while minimizing human infection risks. Rabies control across different regions has depended heavily on veterinary vaccines, which also support global initiatives to stop dog-transmitted human rabies. The medical authorities recommend receiving booster vaccination doses at regular intervals to sustain protection levels, particularly in areas with high risk, driving the global rabies veterinary vaccines market growth. The combination of vaccination initiatives with public education efforts and stray animal control programs serves as the main method to prevent rabies, which safeguards both humans and animals.

For instance, in March 2024, a Spanish National Research Council (Consejo Superior de Investigaciones Cientificas) collaboration with Zendal group launched Neoleish, the world's first DNA vaccine against canine leishmaniasis, a serious zoonosis that can also be transmitted from animals to humans.

Growing Public Awareness Boosts Global Rabies Veterinary Vaccines Market Demand

The rising awareness concerning rabies prevention acts as the main factor that boosts the veterinary vaccine market demand. Nonprofit organizations working with governments and animal welfare groups partner with educational programs that teach pet owners and local populations about the deadly aspects of rabies and vaccination needs. Public health campaigns combine with social media outreach and veterinary initiatives to promote immediate vaccinations for all pets and stray animals, which leads to higher vaccination compliance. The implementation of mandatory vaccination policies in various countries leads people to comply with vaccination rules because they understand rabies as a zoonotic disease. The media uses both rabies outbreak reports and elimination program success stories to show how vaccines protect human lives. The partnership of health authorities with veterinarians and community groups establishes trust in vaccination, which leads to increased immunization of people. The rising awareness and knowledge about rabies lead pet owners to vaccinate their animals and enhance public support for stray animal vaccination programs. The public changes in understanding and behavior regarding rabies vaccines generate significant increases in veterinary vaccine sales, which helps drive worldwide rabies elimination efforts.

Additionally, to raise awareness among the people about the vaccination government is taking the initiative by launching programs. For instance, in September 2024, on World Rabies Day, WHO introduced a theme, 'Breaking Rabies Boundaries,' which means that One Health is not for a selected few but for everyone. This theme calls for new ways of thinking and partnership across sectors and places, centering on the need to harmonize work on human and animal health, as well as environmental health. By getting beyond boundaries, breaking down geographic, socio-economic, and educational barriers, can achieve proper vaccination, awareness, and medical care for everybody. This integrated approach is imperative to combating rabies to create a world where rabies afflict no one, human or canine.

Mandatory Vaccination Policies Fuel Market Growth

The enforcement of mandatory vaccination policies serves as an essential market expansion factor that drives the growth of rabies veterinary vaccines through their widespread use among domestic animals and livestock. Multiple countries, together with their regulatory bodies, enforce mandatory rabies vaccination of animals to stop this deadly disease from spreading among animals and humans. Such regulations generate continuous vaccine demand because domestic animal and livestock owners, together with veterinary medical facilities, must follow established legal vaccination protocols. The market experiences additional growth because public education efforts are combined with free vaccination programs. Pharmaceutical corporations dedicate funds to research and development activities, which result in new cost-effective vaccines designed for both industrialized and developing market regions. The market expands because of rising pet numbers, together with increasing worries about diseases that spread between species. The global rabies veterinary vaccine market will keep increasing due to rigorous vaccination law enforcement and increased government rabies eradication programs in Asia-Pacific and Africa, both of which are regions in which rabies is still endemic.

For instance, in March 2023, to reduce and control the rabies disease government framed the Animal Birth Control (Dogs) Rules to control the population of stray dogs. The focus of the rules is on anti-rabies vaccination of stray dogs and neutering of stray dogs as a means of population stabilization.

Dogs Dominate the Global Rabies Veterinary Vaccines Market

Dogs are the dominant sector in the market for rabies veterinary vaccines as they are the major vectors of transmission to humans. Because rabies is always lethal once symptoms have arisen, stopping transmission via canines is a priority of public health initiatives. Mass canine vaccination campaigns are recognized globally as the most efficient method of decreasing human cases of rabies and, hence, are the main driver of demand for veterinary rabies vaccines. Most countries have mandatory dog vaccination laws, especially in areas where rabies is still prevalent. The increasing population of pet dogs and rabies prevention awareness also supports the dominant market of canine vaccines. Vaccines have been developed for other animals (livestock or wildlife); however, dogs are a priority because they are the animal most likely to be in contact with humans. The eradication of rabies worldwide has emphasized dog vaccination because successful dog vaccination programs have made the domestic canine the center of the veterinary rabies vaccine market. Without a constant dog vaccination program, humans might have a greater resistance to rabies.

For instance, in June 2024, according to the World Health Organization, almost 99% of human rabies infections result from dog-transmitted virus spread. The age group consisting of children between five and fourteen years old experiences the highest number of victims.

North America holds the Largest Global Rabies Vaccines Market Size

North America holds the largest market size of rabies veterinary vaccines due to several key factors, such as the area being served by clear animal vaccination laws, especially for pets such as dogs and cats, which necessitate high demand for rabies vaccines. The veterinary healthcare dynamism in the U.S. and Canada has established government support for rabies prevention. Even more, the growth trajectory in rabies vaccination will be contingent on the increased awareness of zoonotic diseases among the pet-owning public. The presence of major pharmaceutical companies in this market draws confidence for this region, as these companies put significant investment into research and development of and distribution of rabies vaccines. The success of existing wildlife programs in both areas, especially rural areas, has increased demand for rabies vaccinations. Now, North America is in a favorable position, supported by animal health research, an advanced veterinary system, compliance rates with vaccination protocols, and government support. North America will continue to lead the rabies veterinary vaccine market for years to come.

For instance, in June 2024, MSD Animal Health, a division of Merck & Co., Inc., announced the availability of the NOBIVAC NXT Rabies portfolio, comprised of NOBIVAC NXT Feline-3 Rabies and NOBIVAC NXT Canine-3 Rabies in Canada in support of the company's ongoing commitment to rabies protection. The NOBIVAC NXT rabies portfolio is a new and innovative line of vaccines utilizing advanced Ribonucleic acid (RNA) particle technology to protect cats and dogs from rabies.

Impact of U.S. Tariffs on Global Rabies Veterinary Vaccines Market

In the United States, tariffs on rabies veterinary vaccines could increase costs for clinics, pet owners, and livestock producers, resulting in decreased rates of vaccination and increased public health risks. Since domestic production is limited, tariffs will cause shortages, with extra economic burdens placed on animal shelters and less affluent pet owners. It remains true that some domestic manufacturers may compete in a vacuum; however, even with domestically manufactured vaccines, global supply chain breaks may delay the availability of vaccines. If all vaccines imported into the United States cease without adequate production capacity, rabies control efforts may diminish, exposing animal and human populations to greater risks. Tariffs could impose an inefficiency on the market that will raise prices and not increase domestic output, reduce animal disease control and prevention programs, and reduce accessibility.

Key Players Landscape and Outlook

Leading companies develop new vaccines, improve existing ones, and tailor vaccines that serve animal species and geographic areas. Several key players expand their distribution networks by forming partnerships with other companies by making acquisitions or opening local subsidiaries to access emerging markets. The companies dedicate funds to modernize their manufacturing operations and facilities, which results in high-quality vaccine manufacturing. Leasing companies release fresh vaccines that deliver better effectiveness alongside various virus strain targets. Additionally, they collaborate with regulatory authorities to obtain product approvals while meeting legal standards. Community awareness programs operated by the companies deliver education about rabies prevention and explain why vaccination matters. The companies implement sustainable production and distribution methods, which show their dedication to corporate social responsibility.

In March 2024, Zoetis Inc. announced that they have purchased a 21-acre manufacturing facility in Melbourne to expand its current operations at the facility as well as develop new capabilities for the future, to develop and produce vaccines for sheep, cattle, dogs, cats, and horses. At the present time, 130 million doses of vaccines for companion animals and livestock are produced in Australia annually.

In November 2024, Boehringer Ingelheim AG (C.H. Boehringer Sohn AG & Co. KG.) launched the Eurican L4 vaccine for dogs to protect against the growing threat of leptospirosis, a severe and reemerging infectious disease.

Key Players Operating in Global Rabies

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Impact of U.S. Tariffs

4. Executive Summary

5. Global Rabies Veterinary Vaccines Market Outlook, 2018-2032F

  • 5.1. Market Size Analysis & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share Analysis & Forecast
    • 5.2.1. By Application
      • 5.2.1.1. Companion Animals
        • 5.2.1.1.1. Dogs
        • 5.2.1.1.2. Cats
        • 5.2.1.1.3. Rabbits
        • 5.2.1.1.4. Others
      • 5.2.1.2. Livestock Animals
        • 5.2.1.2.1. Cattle
        • 5.2.1.2.2. Sheep
        • 5.2.1.2.3. Goats
        • 5.2.1.2.4. Others
      • 5.2.1.3. Others
    • 5.2.2. By Distribution Channel
      • 5.2.2.1. Retail
      • 5.2.2.2. E-Commerce
      • 5.2.2.3. Hospital/Clinic Pharmacies
    • 5.2.3. By Region
      • 5.2.3.1. North America
      • 5.2.3.2. Europe
      • 5.2.3.3. Asia-Pacific
      • 5.2.3.4. South America
      • 5.2.3.5. Middle East and Africa
    • 5.2.4. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
  • 5.3. Market Map Analysis, 2024
    • 5.3.1. By Application
    • 5.3.2. By Distribution Channel
    • 5.3.3. By Region

6. North America Rabies Veterinary Vaccines Market Outlook, 2018-2032F

  • 6.1. Market Size Analysis & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share Analysis & Forecast
    • 6.2.1. By Application
      • 6.2.1.1. Companion Animals
        • 6.2.1.1.1. Dogs
        • 6.2.1.1.2. Cats
        • 6.2.1.1.3. Rabbits
        • 6.2.1.1.4. Others
      • 6.2.1.2. Livestock Animals
        • 6.2.1.2.1. Cattle
        • 6.2.1.2.2. Sheep
        • 6.2.1.2.3. Goats
        • 6.2.1.2.4. Others
      • 6.2.1.3. Others
    • 6.2.2. By Distribution Channel
      • 6.2.2.1. Retail
      • 6.2.2.2. E-Commerce
      • 6.2.2.3. Hospital/Clinic Pharmacies
    • 6.2.3. By Country Share
      • 6.2.3.1. United States
      • 6.2.3.2. Canada
      • 6.2.3.3. Mexico
  • 6.3. Country Market Assessment
    • 6.3.1. United States Rabies Veterinary Vaccines Market Outlook, 2018-2032F*
      • 6.3.1.1. Market Size Analysis & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share Analysis & Forecast
        • 6.3.1.2.1. By Application
          • 6.3.1.2.1.1. Companion Animals
          • 6.3.1.2.1.1.1. Dogs
          • 6.3.1.2.1.1.2. Cats
          • 6.3.1.2.1.1.3. Rabbits
          • 6.3.1.2.1.1.4. Others
          • 6.3.1.2.1.2. Livestock Animals
          • 6.3.1.2.1.2.1. Cattle
          • 6.3.1.2.1.2.2. Sheep
          • 6.3.1.2.1.2.3. Goats
          • 6.3.1.2.1.2.4. Others
          • 6.3.1.2.1.3. Others
        • 6.3.1.2.2. By Distribution Channel
          • 6.3.1.2.2.1. Retail
          • 6.3.1.2.2.2. E-Commerce
          • 6.3.1.2.2.3. Hospital/Clinic Pharmacies
    • 6.3.2. Canada
    • 6.3.3. Mexico

All segments will be provided for all regions and countries covered

7. Europe Rabies Veterinary Vaccines Market Outlook, 2018-2032F

  • 7.1. Germany
  • 7.2. France
  • 7.3. Italy
  • 7.4. United Kingdom
  • 7.5. Russia
  • 7.6. Netherlands
  • 7.7. Spain
  • 7.8. Turkey
  • 7.9. Poland

8. Asia-Pacific Rabies Veterinary Vaccines Market Outlook, 2018-2032F

  • 8.1. India
  • 8.2. China
  • 8.3. Japan
  • 8.4. Australia
  • 8.5. Vietnam
  • 8.6. South Korea
  • 8.7. Indonesia
  • 8.8. Philippines

9. South America Rabies Veterinary Vaccines Market Outlook, 2018-2032F

  • 9.1. Brazil
  • 9.2. Argentina

10. Middle East and Africa Rabies Veterinary Vaccines Market Outlook, 2018-2032F

  • 10.1. Saudi Arabia
  • 10.2. UAE
  • 10.3. South Africa

11. Demand Supply Analysis

12. Value Chain Analysis

13. Porter's Five Forces Analysis

14. PESTLE Analysis

15. Pricing Analysis

16. Market Dynamics

  • 16.1. Market Drivers
  • 16.2. Market Challenges

17. Market Trends and Developments

  • 17.1. Technology Analysis

18. Regulatory Framework and Innovation

19. Case Studies

20. Competitive Landscape

  • 20.1. Competition Matrix of Top 5 Market Leaders
  • 20.2. SWOT Analysis for Top 5 Players
  • 20.3. Key Players Landscape for Top 10 Market Players
    • 20.3.1. Zoetis Inc.
      • 20.3.1.1. Company Details
      • 20.3.1.2. Key Management Personnel
      • 20.3.1.3. Products and Services
      • 20.3.1.4. Financials (As Reported)
      • 20.3.1.5. Key Market Focus and Geographical Presence
      • 20.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
    • 20.3.2. Merck & Co., Inc
    • 20.3.3. C.H. Boehringer Sohn AG & Co. KG. (Parent Company)
    • 20.3.4. ELANCO ANIMAL HEALTH INCORPORATED
    • 20.3.5. Virbac SA
    • 20.3.6. Laboratorios HIPRA, S.A.
    • 20.3.7. Neogen Corporation
    • 20.3.8. HESTER BIOSCIENCES LIMITED
    • 20.3.9. Phibro Animal Health Corporation
    • 20.3.10. Ceva Sante Animale SA

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

21. Strategic Recommendations

22. About Us and Disclaimer